Myriad Completes Spin Off of Pharma Business | GenomeWeb

NEW YORK (GenomeWeb News) – Myriad Genetics said after the close of the market Wednesday that it has completed the spin off of Myriad Pharmaceuticals.

The spin off happened on schedule, with Myriad Genetics' shareholders of record as of June 17, receiving a pro-rata dividend of one quarter of a share of Myriad Pharmaceuticals for each share of Myriad Genetics. Fractional shares were paid in cash, the firm said.

As of yesterday, Myriad Genetics has no ownership of Myriad Pharmaceuticals, and the two firms operate completely independently of each other.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.